Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2015 Jun 30;113(2):252–258. doi: 10.1038/bjc.2015.170

miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells

T Higashi 1, H Hayashi 1, T Ishimoto 1, H Takeyama 1, T Kaida 1, K Arima 1, K Taki 1, K Sakamoto 1, H Kuroki 1, H Okabe 1, H Nitta 1, D Hashimoto 1, A Chikamoto 1, T Beppu 1, H Baba 1,*
PMCID: PMC4506379  PMID: 26125451

Abstract

Background:

The inactivation of the Hippo pathway lead to TAZ (PDZ-binding motif)/YAP (yes-associated protein) overexpression, and is associated with worse prognostic outcomes in various cancers including hepatocellular carcinoma (HCC). Although there are several reports of microRNA (miR) targeting for YAP, miR targeting for TAZ remains unclear. The aim of this study is to identify the miR targeting TAZ expression in HCC.

Methods:

MicroRNA expression was analysed using the Human miFinder 384HC miScript miR PCR array, and was compared between low and high TAZ expression cell lines. Then, we extracted miR-9-3p as a tumour-suppressor miR targeting TAZ. We examined the functional role of miR-9-3p using miR-9-3p mimic and inhibitor in HCC cell lines).

Results:

In HCC cell lines and HCC clinical samples, there was the inverse correlation between miR-9-3p and TAZ expressions. TAZ expression was induced by treatment of miR-9-3p inhibitor and was downregulated by treatment of miR-9-3p mimic. Treatment of miR-9-3p mimic inhibited cell proliferative ability with downregulated phosphorylations of Erk1/2, AKT, and β-catenin in HLF. Inversely, treatment of miR-9-3p inhibitor accelerated cell growth compared with control in HuH1.

Conclusions:

MicroRNA-9-3p was identified as the tumour-suppressor miR targetting TAZ expression in HCC cells.

Keywords: microRNA, Hippo pathway, TAZ, hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death (Forner et al, 2012). Despite recent advances in cancer treatment including the development of molecular-targeted drugs, the prognosis of patients with HCC remains poor. In 2003, the Hippo pathway was identified as a novel signalling cascade that controls organ size by inhibiting cell proliferation and promoting apoptosis (Wu et al, 2003; Ramos and Camargo, 2012). Defects in the Hippo pathway induce the hyperactivation of its downstream effectors such as transcriptional co-activator with PDZ-binding motif (TAZ) and yes-associated protein (YAP) (Qin et al, 2013); their overexpression is often detectable and is associated with worse prognostic outcome in various cancers including HCC (Zhao et al, 2007; Xu et al, 2009; Liu et al, 2010b; Zhao et al, 2012; Huo et al, 2013; Yuen et al, 2013; Bartucci et al, 2014; Han et al, 2014; Ma et al, 2014), suggesting that TAZ and YAP could be novel therapeutic targets.

MicroRNAs (miRs) are small non-coding RNAs that repress the translation of their target mRNAs by base pairing to partially complementary sequences in their 3′-untranslated region (UTR). MicroRNAs have important regulatory functions in processes such as differentiation, proliferation, and inhibiting apoptosis (Chen et al, 2004; Croce and Calin, 2005), and regulate the expression of many target genes, and dysregulation of miRs are associated with various cancers. Although there are some reports of miR targeting of YAP, such as miR-375 (Liu et al, 2010a), -135b (Lin et al, 2013), -29 (Tumaneng et al, 2012), and -let7 (Chen et al, 2012), there are no reports of miR targeting of TAZ. The aim of this study was to identify the miR that controls TAZ expression in HCC.

Materials and Methods

Cell lines and culture

Established HCC cell lines (HepG2, HuH1, HuH7, HLE, HLF, PLC, and SKHep1) were used in the current study. These cell lines were obtained from the Japanese Collection of Research Bioresources Cell Bank and Riken BioResource Center Cell Bank. All lines were cultured under 5% CO2 at 37 °C in Dulbecco's modified Eagle's medium (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS). All cultures were maintained in a 5% CO2 air-humidified atmosphere at 37 °C.

RNA and miRNA isolation

Total RNA was isolated from cell lines and frozen tissues using a miRNeasy Mini Kits (Qiagen, Valencia, CA, USA) and finally eluted into 30 μl of heated elution solution, according to the manufacturer's protocol. The purity and concentration of all RNA samples was evaluated by their absorbance ratio at 260/280 nm, determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA).

MicroRNA PCR array

MicroRNA expression was analysed using the Human miFinder 384HC miScript miRNA PCR Array (Qiagen; MIHS-3001Z), which profiles the expression of the 372 most abundantly expressed and best-characterised miRNAs in miRBase, according to the manufacturer's instructions.

Luciferase assays

HLF cells in 96-well plates were transfected with pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Tokyo, Japan: E1330) containing firefly luciferase and renilla luciferase, and Luc-TAZ-a, aM, b, bM, or control (non-insert), and mimic negative control (NC) or mimic miR-9-3p (Invitrogen, Carlsbad, CA, USA) using MultiFectam (Promega: ETF5000). Reporter assays were performed at 48 h after transfection, and firefly and renilla luciferase activities were measured using the Dual-Glo Luciferase Assay System (Promega: E2940). All transfection experiments were conducted in triplicate.

Quantitative real-time reverse transcription PCR

The expression levels of miR-9-3p were determined by quantitative real-time reverse transcription PCR (qRT–PCR) using TaqMan MicroRNA Assay Kits (Applied Biosystems, Foster City, CA, USA). For synthesis of cDNA, 10 ng of total RNA for each serum sample was used for individual assays in a 15-μl reaction mixture containing 5 μl RNA extract, 0.15 μl of 100 mM dNTPs, 1 μl multiscribe reverse transcriptase (50 U ml−1), 1.5 μl of 109 reverse transcription buffer, 0.19 μl RNase inhibitor (20 U ml−1), 1 μl gene-specific TaqMan primer (Supplementary Table 1), and 4.16 μl nuclease-free water. TAZ expression levels were quantified by SYBR Green qRT–PCR using a LightCycler 480 SYBR Green I Master (Roche Diagnostics, Mannheim, Germany) and normalised to ACTB (β-actin). The reaction mixture was incubated at 16 °C for 30 min, 42 °C for 60 min, and 85 °C for 5 min. Subsequently, 5 μl cDNA template was amplified using 10 μl LightCycler 480 SYBR Green I Master (Roche Diagnostics), 3 μl of nuclease-free water, and 2 μl gene-specific primers (Supplementary Table 1) mix in a final volume of 20 μl. Quantitative RT–PCR was run on a LightCycler 480 System II (Roche Diagnostics). The reaction mixture was incubated at 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 1 s. All qRT–PCRs were run using the LightCycler 480 System II (Roche Diagnostics). The relative amounts of miR-9-3p and TAZ were measured with the 2−ΔΔCT method. All qRT–PCRs were performed in triplicate.

MicroRNA transfection

Cells were transfected with 20 nM miR-9-3p mimic or inhibitor (Applied Biosystems) using Lipofectamine 2000 or RNAiMax transfection reagent (Invitrogen), according to the manufacturer's instructions. The specificity of the transfection was verified using a NC mimic (Applied Biosystems). The expression levels of miR-9-3p were quantified 48 h after transfection, and the cells were used for subsequent experiments.

Western blot analysis

To isolate the proteins, cells collected from six-well plates were washed once in phosphate-buffered saline and lysed in RIPA buffer. Each protein sample (12 μg) was resolved by SDS–polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membranes, and incubated with monoclonal antibodies, as follows: TAZ/YAP (1:1000; Cell Signaling, Danvers, MA, USA), N-cadherin (1:1000; clone 56, BD Biosciences, Tokyo, Japan), E-cadherin (1:1000; Cell Signaling), phosphorylated-AKT (p-AKT; 1:1000; Cell Signaling), AKT (1:1000; Cell Signaling), phosphorylated-ERK1/2 (p-ERK1/2; 1:1000; Cell Signaling), ERK1/2 (1:1000; Cell Signaling), phosphorylated β-catenin (p-β-catenin; 1:1000; Cell Signaling), β-catenin (1:1000; Cell Signaling), β-actin (1:2000; Cell Signaling), α-tubulin (1:20 000; Abcam, Cambridge, MA, USA), or histone H3 (1:20 000; Abcam). The signals were detected by incubation with secondary antibodies labelled with the ECL Detection System (GE Healthcare, Little Chalfont, UK).

Cell fractionation

To prepare cytoplasmic and nuclear extracts for western blotting, transfected cell pellets were resuspended in hypotonic buffer (20 mM HEPES (pH 8.0), 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, and 20% glycerol) and incubated on ice for 10 min. Cytoplasmic fractions were obtained by collecting supernatants following centrifugation at 1500 g for 5 min. Pellets were washed twice in hypotonic buffer, centrifuged at 5000 g for 5 min, and lysed on ice for 1 h in RIPA buffer (50 mM Tris (pH 7.5) 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% NP40) followed by centrifugation at 21 000 g for 10 min. All buffers were supplemented with complete protease inhibitor cocktail (Thermo Scientific, Waltham, MA, USA).

Invasion assay

Biocoat Matrigel-coated invasion chambers (BD Biosciences, San Jose, CA, USA) were used to examine cell invasion. In brief, 1.0 × 105 HLF and 1.5 × 105 HuH1 cells in 500 μl serum-free medium were added to the upper chamber. Medium containing 10% FBS was added to the lower chamber. The cells were allowed to invade the Matrigel for 24 h at 37 °C in 5% CO2 atmosphere. After 22 h, the non-invading cells were removed with a cotton swab, and the invading cells were stained with 1% toluidine blue and counted under a microscope at × 20 magnification.

Proliferation assay

Cells were seeded in a 96-well plate at a density of 2000 cells per well. The medium in each well was changed daily. Viable cell numbers were measured with a Cell Counting Kit-8 containing 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8; Dojin Laboratories, Kumamoto, Japan) for 0, 24, 48, 72, and 96 h, according to the manufacturer's instructions. Optical density (450 nm) was measured using an automatic microplate reader (Molecular Devices, Osaka, Japan). Each experiment was performed in triplicate.

Clinical samples

Frozen HCC tissue was obtained from patients who had undergone hepatic resection. The study was approved by the Medical Ethics Committee of Kumamoto University, and written informed consent was obtained from the human subjects.

Statistical analysis

Statistical analyses were performed using the JMP programme (SAS Institute, Cary, NC, USA). Quantitative data were expressed as mean±s.d., unless otherwise stated. The χ2-test was used to analyse relationships between categorical variables. P<0.05 was considered significant.

Results

Identification of miRs regulating TAZ expression using cancer-related miR screening in HCC cell lines

We first examined the expression profile of TAZ/YAP by western blotting in seven HCC cell lines (HepG2, HuH1, HuH7, HLE, HLF, PLC, and SKHep1). TAZ protein was the predominant expression profile in HCC cell lines (Figure 1A). By qRT–PCR, HepG2, HLE, and HLF revealed high TAZ mRNA levels, whereas HuH1, PLC, and SKHep1 expressed low levels (Figure 1B). To identify the miRs that regulate TAZ expression, miR qRT–PCR array analysis was performed to compare the high TAZ-expressing cell lines (HepG2, HLE, and HLF) and the low TAZ-expressing cell lines (HuH1, PLC, and SKHep1). Twenty-four miRs showed low expression in high TAZ-expressing cells by less than three-fold compared with the low TAZ-expressing cell group (Table 1). In addition, 133 miRs were highlighted as candidates that directly target human TAZ 3′-UTR using online databases (miRTarBase, TarBase, microRNA.org, and TargetScanHuman). Finally, miR-9-3p was extracted as a candidate that met both requirements (Figure 1C).

Figure 1.

Figure 1

Open in a new tab

Identification of miRs regulating TAZ expression via cancer-related miR screening in HCC cell lines. (A and B) TAZ and YAP expression in seven HCC cell lines by qRT–PCR and western blot analysis. (C) Analysis of the Human miFinder 384HC miScript miRNA PCR Array. Twenty-four miRs showed low expression by less than three-fold in high TAZ-expressing cells (HepG2, HLE, and HLF) compared with low TAZ-expressing cells (HuH1, PLC, and SKHep1). Of 133 miRs that were highlighted as candidates directly targeting the human TAZ 3′-UTR using online databases, miR-9-3p directly targeted TAZ.

Table 1. MicroRNAs lists showing low expression in high TAZ-expressing cell group with less than three-fold compared with low TAZ-expressing cell group.

miRs Folds change
let-7b-5p 4.6
miR-122-5p 15.7
miR-122-3p 6.9
miR-126-3p 8.9
miR-126-5p 8.6
miR-135a-5p 7.6
miR-135b-5p 4.0
miR-149-5p 4.2
miR-155-5p 5.8
miR-182-3p 4.2
miR-192-5p 9.4
miR-192-3p 7.1
miR-194-5p 6.5
miR-196a-5p 5.1
miR-196b-5p 14.2
miR-203a 5.6
miR-208a 8.8
miR-215 7.3
miR-218-1-3p 9.3
miR-34a-3p 4.4
miR-424-5p 6.0
miR-551b-3p 15.1
miR-9-5p 7.5
miR-9-3p 6.8
Open in a new tab

TAZ as a direct binding target of miR-9-3p

Next, using luciferase reporter assays, we confirmed whether miR-9-3p targeted the 3′-UTR of TAZ mRNA. The predicted target sequence of miR-9-3p in the TAZ 3′-UTR was checked using the miRanda algorithm. Luc-TAZ-a and -b represent alignments of the predicted miR-9-3p target sequences in the wild-type TAZ 3′-UTR mRNA. Seed sequences are indicated by lines in Figure 2A. HLF cells transfected with a miR-9-3p mimic significantly suppressed luciferase activity from the reporter vectors containing Luc-TAZ-a but not Luc-TAZ-b compared with the control vectors (P<0.001; Figure 2B). We also constructed reporter vectors containing the mutated TAZ 3′-UTR (Luc-TAZ-aM and Luc-TAZ-bM). HLF cells transfected with a miR-9-3p mimic failed to suppress luciferase activity from the reporter vectors containing the mutated 3′-UTR of TAZ compared with the wild-type 3′-UTR-containing vector (Figure 2B). These results indicated that miR-9-3p regulated TAZ expression by directly targeting its 3′-UTR.

Figure 2.

Figure 2

Open in a new tab

TAZ as a direct binding target of miR-9-3p. (A) The predicted target sequence of miR-9-3p in the TAZ 3′-UTR. (B) Luciferase reporter assays to establish whether miR-9-3p targeted the 3′-UTR of TAZ mRNA. HLF cells transfected with a miR-9-3p mimic significantly suppressed Luc-TAZ-a but not Luc-TAZ-b luciferase activity compared with the control vectors (P<0.001). HLF cells transfected with a miR-9-3p mimic did not suppress Luc-TAZ-aM and Luc-TAZ-bM luciferase activity compared with the wild-type 3′-UTR-containing vector. (C) Analysis of TAZ expression levels in cells transfected with miR-9-3p mimic and inhibitor by western blotting. TAZ protein levels were reduced in HLF cells transfected with miR-9-3p mimic compared with the controls, and the levels were increased in HuH1 cells treated with miR-9-3p inhibitor. (D) miR-9-3p mimic and inhibitor also influenced TAZ localisation. HuH1 cells treated with miR-9-3p inhibitor revealed upregulated TAZ expression and accelerated the nuclear localisation of TAZ. The converse results were confirmed in HLF cells treated with miR-9-3p mimic.

We investigated whether miR-9-3p successfully modulated TAZ protein expression in HLF cells with high TAZ expression and HuH1 cells with low TAZ expression. HLF cells transfected with miR-9-3p mimic showed decreased TAZ protein levels, whereas HuH1 cells treated with miR-9-3p inhibitor displayed increased TAZ protein levels in comparison with the controls (Figure 2C). TAZ nuclear localisation was indeed inhibited with miR-9-3p mimic treatment in HLF cells, and was upregulated by miR-9-3p inhibitor treatment in HuH1 cells (Figure 2D). In 55 human HCC tissues, we examined miR-9-3p and TAZ expression levels using qRT–PCR. We divided them into two subgroups according to their miR-9-3p expression (low vs. high) based on the median value. Cancer tissues with high miR-9-3p expression displayed significantly lower TAZ mRNA levels compared with those exhibiting high miR-9-3p expression (P=0.016; Figure 3A). There was an inverse correlation between miR-9-3p and TAZ mRNA expression in HCC cell lines (Figure 3B).

Figure 3.

Figure 3

Open in a new tab

Inverse correlation between miR-9-3p and TAZ mRNA expressions in HCC patients. (A) High miR-9-3p expression was significantly associated with low TAZ mRNA level in HCC (P=0.016). (B) There was an inverse correlation between miR-9-3p and TAZ mRNA expressions in HCC cell lines.

miR-9-3p promotes cancer cell proliferation but not invasiveness by modulating AKT, ERK1/2, and β-catenin signalling

We examined the functional relevance of miR-9-3p expression in cancer cells. HLF cells transfected with miR-9-3p mimic showed significantly reduced cell proliferation compared with the control (P<0.01; Figure 4A). Inversely, HuH1 cells treated with miR-9-3p inhibitor displayed accelerated cell proliferation compared with the control (P<0.01; Figure 4A). The expression of p-AKT, p-ERK1/2, and p-β-catenin was decreased by transfection with miR-9-3p mimic. Treatment with miR-9-3p inhibitor increased these expression patterns (Figure 4B). These results indicated that miR-9-3p had a crucial role in cancer cell proliferation via AKT, ERK, and β-catenin signalling in HCC cells.

Figure 4.

Figure 4

Open in a new tab

miR-9-3p affects cancer cell proliferation, but not invasiveness. (A) Cell proliferation was significantly reduced in HLF cells transfected with miR-9-3p mimics compared with the controls; an inverse result was shown in HuH1 cells treated with miR-9-3p inhibitors (P<0.01). (B) Phosphorylation of AKT (p-AKT), ERK (p-ERK), and β-catenin (p-β-catenin) was decreased by transfection with miR-9-3p mimic. Treatment with miR-9-3p inhibitor increased these expression. (C) The protein levels of E- and N-cadherin were not altered by miR-9-3p mimics and inhibitors. (D) Cell invasiveness was not affected by miR-9-3p mimics and inhibitors.

With regard to cell invasiveness, the protein levels of E- and N-cadherin were not affected by the miR-9-3p mimic and inhibitor (Figure 4C). Cell invasiveness was also not affected by the miR-9-3p mimic and inhibitor (Figure 4D).

Discussion

Although TAZ and YAP are downstream effectors in the Hippo pathway, TAZ is the predominantly expressed protein in HCC cells, suggesting that TAZ appears to be a therapeutic target in HCC. The function of TAZ has become evident in several cancers. For example, TAZ has a critical role in migration, invasion, and tumorigenesis in breast cancer cells (Chan et al, 2008). It has been reported that TAZ promotes cell proliferation in lung cancer cells (Zhou et al, 2011). Clinically, TAZ overexpression is associated with poor prognosis in breast, lung, and colorectal cancer patients (Yuen et al, 2013; Bartucci et al, 2014; Noguchi et al, 2014). In the present study, we did not found any phenotypical change of cell invasiveness in HCC cells by miR-9-3p mimic and inhibitor. Previously, Chan et al (2008) published that TAZ promoted the migration and invasion in breast cancer cells in Cancer Research. Guo et al (2015) also reported a similar promotion of the same phenotype in HCC cells in Journal of Cellular Biochemistry. Although there are many regulators of TAZ expression, miR-9-3p-mediated TAZ expression may participate in cell proliferation, but not in cell invasiveness. Currently, the potential of miRs as anticancer therapeutic targets has been extensively investigated. There are several reports of miRs (such as miR-375 (Liu et al, 2010a), -135 (Lin et al, 2013), -29 (Tumaneng et al, 2012), -let7 (Chaulk et al, 2014), and miR-31 (Mitamura et al, 2014)) targeting the Hippo pathway, including YAP, which is another downstream effector of the Hippo pathway (Table 2). However, there are no reports of miRs targeting TAZ; this is the first report of a miR that regulates TAZ. TAZ is known to have oncogenic properties in several gastroenterological cancers including HCC (Yuen et al, 2013; Han et al, 2014). In the present study, overexpression of miR-9-3p using a mimic decreased TAZ expression and resulted in suppressed cell proliferation in HCC. Inversely, inhibition of miR-9-3p induced TAZ expression and promoted proliferation in HCC cells. Thus, miR-9-3p had an onco-suppressive role in HCC cells by downregulating TAZ. These findings suggest that miR-9-3p could be a pharmacological target in HCC.

Table 2. The list of microRNAs targeting the Hippo pathway.

First author Journal Year MicroRNA Target gene
Chaulk SG J Biol Chem 2014 miR-let7 YAP
Mitamura T Mol Cancer 2014 miR-31 LATS2
Zhang ZW Cell Physiol Biochem 2013 miR-375 YAP
Lin CW Nat Commun 2013 miR-135b LATS2
Tumaneng K Nat Cell Biol 2012 miR-29 YAP
Present study     miR-9-3p TAZ
Open in a new tab

miR-9 is known as a brain-enriched miR. In brain cancer, miR-9 has been mostly reported as an oncogene. However, miR-9 has been also thought to function as both an oncogene and a tumour-suppressor gene. It is overexpressed in brain cancers such as medulloblastoma (Fiaschetti et al, 2014) and glioma (Jeon et al, 2011). Furthermore, high expression of miR-9 was associated with poor survival in medulloblastoma patients (Adam et al, 2010). However, it showed anticancer effects in other cancer types such as breast cancer (Selcuklu et al, 2012; Zawistowski et al, 2013),oral squamous cell carcinoma (Yu et al, 2013), and gastric cancer (Zheng et al, 2013). Furthermore, high expression of miR-9 was associated with poor survival in patients with breast cancer (Zhou et al, 2012) and medulloblastoma (Adam et al, 2010).

We investigated the relationship between miR-9-3p and TAZ, and then confirmed the inverse association between miR-9-3p expression and TAZ mRNA expression in HCC clinical samples. Although high TAZ protein expression has been reported to be associated with worse prognostic outcome in HCC patients, it was hard to conclude the prognostic significance of miR-9-3p in the present study with the small and limited number of clinical samples (frozen tissues) available. Further study is required to determine the clinical relevance of miR-9-3p in a large number of HCC patients.

In conclusion, we have identified miR-9-3 as a tumour-suppressing miR targeting TAZ expression in HCC cells. miR-9-3p has a crucial role in cell proliferation, but not invasion, via AKT, ERK1/2, and β-catenin signalling in HCC cells.

Acknowledgments

We thank Mr Keisuke Miyake, Ms Naomi Yokoyama, and Ms Yoko Ogata for their kind support in preparing experiment reagents.

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License

Supplementary Material

Supplementary Table 1
Click here for additional data file. (30KB, doc)

References

  1. Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, Poston GJ, Wicherts DA, de Haas RJ, LiverMetSurvey C. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97 (3:366–376. doi: 10.1002/bjs.6889. [DOI] [PubMed] [Google Scholar]
  2. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Sacca M, Piccolo S, De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2014;34 (6:681–690. doi: 10.1038/onc.2014.5. [DOI] [PubMed] [Google Scholar]
  3. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68 (8:2592–2598. doi: 10.1158/0008-5472.CAN-07-2696. [DOI] [PubMed] [Google Scholar]
  4. Chaulk SG, Lattanzi VJ, Hiemer SE, Fahlman RP, Varelas X. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. J Biol Chem. 2014;289 (4:1886–1891. doi: 10.1074/jbc.C113.529362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303 (5654:83–86. doi: 10.1126/science.1091903. [DOI] [PubMed] [Google Scholar]
  6. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18 (10:1511–1517. doi: 10.1038/nm.2940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122 (1:6–7. doi: 10.1016/j.cell.2005.06.036. [DOI] [PubMed] [Google Scholar]
  8. Fiaschetti G, Abela L, Nonoguchi N, Dubuc AM, Remke M, Boro A, Grunder E, Siler U, Ohgaki H, Taylor MD, Baumgartner M, Shalaby T, Grotzer MA. Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. Br J Cancer. 2014;110 (3:636–647. doi: 10.1038/bjc.2013.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379 (9822:1245–1255. doi: 10.1016/S0140-6736(11)61347-0. [DOI] [PubMed] [Google Scholar]
  10. Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W, Shen L.Functional and Clinical Evidence that TAZ is a Candidate Oncogene in Hepatocellular Carcinoma J Cell Biocheme-pub ahead of print 3 February 2015doi: 10.1002/jcb.25117 [DOI] [PubMed]
  11. Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014;2014:261365. doi: 10.1155/2014/261365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep. 2013;29 (2:840–846. doi: 10.3892/or.2012.2176. [DOI] [PubMed] [Google Scholar]
  13. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011;71 (9:3410–3421. doi: 10.1158/0008-5472.CAN-10-3340. [DOI] [PubMed] [Google Scholar]
  14. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, Yang PC. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun. 2013;4:1877. doi: 10.1038/ncomms2876. [DOI] [PubMed] [Google Scholar]
  15. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394 (3:623–627. doi: 10.1016/j.bbrc.2010.03.036. [DOI] [PubMed] [Google Scholar]
  16. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120 (4:1298–1309. doi: 10.1172/JCI39566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ma Y, Yang Y, Wang F, Wei Q, Qin H. Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer. 2014;14 (1:96–105. doi: 10.1002/ijc.29073. [DOI] [PubMed] [Google Scholar]
  18. Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N. microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer. 2014;13:97. doi: 10.1186/1476-4598-13-97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, Konig H, Lohr M, Edlund K, Botling J, Micke P, Nagase T. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin Cancer Res. 2014;20 (17:4660–4672. doi: 10.1158/1078-0432.CCR-13-3328. [DOI] [PubMed] [Google Scholar]
  20. Qin F, Tian J, Zhou D, Chen L. Mst1 and Mst2 kinases: regulations and diseases. Cell Biosci. 2013;3 (1:31. doi: 10.1186/2045-3701-3-31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012;22 (7:339–346. doi: 10.1016/j.tcb.2012.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Selcuklu SD, Donoghue MT, Rehmet K, de Souza Gomes M, Fort A, Kovvuru P, Muniyappa MK, Kerin MJ, Enright AJ, Spillane C. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Bio Chem. 2012;287 (35:29516–29528. doi: 10.1074/jbc.M111.335943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 2012;14 (12:1322–1329. doi: 10.1038/ncb2615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114 (4:445–456. doi: 10.1016/s0092-8674(03)00549-x. [DOI] [PubMed] [Google Scholar]
  25. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115 (19:4576–4585. doi: 10.1002/cncr.24495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q, Wang Z. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene. 2013;33 (42:5017–5027. doi: 10.1038/onc.2013.448. [DOI] [PubMed] [Google Scholar]
  27. Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD, Hong W. TAZ expression as a prognostic indicator in colorectal cancer. PloS one. 2013;8 (1:e54211. doi: 10.1371/journal.pone.0054211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets beta1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol Cell Biol. 2013;33 (11:2260–2274. doi: 10.1128/MCB.00269-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012;26 (1:54–68. doi: 10.1101/gad.173435.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21 (21:2747–2761. doi: 10.1101/gad.1602907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K, Tong Q. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PloS One. 2013;8 (1:e55719. doi: 10.1371/journal.pone.0055719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, Zheng YL. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PloS One. 2012;7 (6:e39011. doi: 10.1371/journal.pone.0039011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011;30 (18:2181–2186. doi: 10.1038/onc.2010.606. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1
Click here for additional data file. (30KB, doc)

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES